What If Healthcare Only Paid When Treatments Actually Worked?

Why This Matters: The Rising Cost of Cures

Gene and cell therapies offer the possibility of once-and-done cures for serious diseases such as sickle cell disease — a hereditary blood disorder that causes chronic pain, organ damage, and reduced lifespan. But the price tags for these treatments routinely exceed $2 million per patient, making them prohibitively expensive under traditional pricing models. (WAMC)

Under the conventional system, insurers and government programs like Medicaid pay the full cost of a treatment regardless of patient outcomes — even if the therapy provides little or no long-term benefit. (WAMC)

A New Idea: Pay Only If It Works

To address these challenges, the Centers for Medicare & Medicaid Services (CMS) has launched a pioneering initiative called the Cell and Gene Therapy (CGT) Access Model. Under this model, Medicaid negotiates outcomes-based agreements (OBAs) with gene therapy manufacturers that tie payment to real-world clinical success. (CMS)

Here’s how it works:

• The federal government negotiates pricing terms with drug makers on behalf of participating state Medicaid programs. (CMS)

• States that join — currently 33 states, plus Washington, D.C., and Puerto Rico — represent about 84% of Medicaid enrollees with sickle cell disease. (cellgenetherapyreview.com)

• If the gene therapy fails to deliver its promised benefits, manufacturers provide rebates or discounts to the states. (CMS)

• The goal is to ensure that Medicaid only pays full price when the therapy significantly improves patient health. (CMS)

This approach marks a major shift from fee-for-service models toward value-based care — a concept long discussed by healthcare economists but rarely implemented at scale. (HHS.gov)

What This Means for Patients

One early beneficiary of the model is 18-year-old Serenity Cole, who was one of the first Medicaid enrollees to receive gene therapy for sickle cell disease under the new payment system. Her treatment aims to reprogram her stem cells so they produce healthy red blood cells — potentially ending the painful crises that once defined her life. (WAMC)

These gene therapies — such as exa-cel and lovo-cel — are approved by the FDA for people aged 12 and older and can dramatically reduce vaso-occlusive events, hospitalizations, and chronic pain. (CMS)

For many patients who previously had limited treatment options beyond pain management and blood transfusions, this model offers real hope for long-term relief — and potentially a cure. (WAMC)

Why Outcomes-Based Payment Could Be a Game-Changer

Medicaid’s experiment has broader implications:

🩺 Reduces Financial Risk for Payers

States gain protection against paying the full cost of multimillion-dollar therapies that don’t yield meaningful results. (CMS)

💊 Encourages Drug Makers to Demonstrate Value

Manufacturers must prove their products work in the real world — not just in controlled clinical trials. (CMS)

🌍 Expands Access for Patients

By sharing negotiation power and offering rebates for poor outcomes, more Medicaid enrollees can receive cutting-edge treatments without excessive restrictions. (WAMC)

💡 Paves the Way for Other Conditions

If successful, the model could expand to other high-cost diseases and therapies, including certain cancers and rare genetic disorders. (CMS)

Challenges and Next Steps

Despite its promise, this payment model is not without hurdles:

• The terms of the negotiated contracts are confidential, making it difficult to evaluate long-term financial impacts. (kgou.org)

• Some state officials caution that early data on outcomes are limited, since clinical trials included small patient populations followed for only a few years. (WAMC)

• Scaling the model to other conditions and insurers may require extensive legal and regulatory adjustments.

Nevertheless, CMS officials and health economists alike see this as a critical test case for value-based pricing in medicine. (CMS)

A New Era in Healthcare Payment

Medicaid’s outcomes-based payment model represents a bold reimagining of how healthcare dollars are spent — shifting focus from volume to value. By aligning payment with patient outcomes, the program is redefining who benefits from medical innovation and ensuring that high costs are matched by real health improvements.

As this model rolls out and collects more data, policymakers, insurers, and healthcare providers will be watching closely. If successful, this strategy may serve as a blueprint for a more equitable and sustainable system for delivering lifelong cures — not just expensive treatments.

Sources You Can Link To

• CMS CGT Access Model details and state participation — CMS.gov (official) (CMS)

• Medicaid’s new outcomes-based sickle cell therapy payment model story — WAMC/KFF Health News (WAMC)

• CMS announcement on multi-state participation and model expansion — CellGeneTherapyReview.com (cellgenetherapyreview.com)